CTIM-76 weekly dosing at 140–280 µg in heavily pretreated PROC: 22% confirmed ORR, 56% confirmed DCR, and median PFS of 5.6 months

Context Therapeutics remains a high-risk, clinical-stage biotechnology firm whose valuation is entirely tethered to the successful advancement of its ONA-XR and CLDN6 programs.
Price trend, volume and key moving averages
Trailing total returns as of 11/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 10, 2026 | -$0.08+25.6% vs -$0.11 | — vs — |
Q3 2026 Aug 5, 2026 | -$0.15-62.8% vs -$0.09 | — vs — |
Q2 2026 May 6, 2026 | -$0.09+25.0% vs -$0.12 | — vs — |
Q2 2026 Mar 19, 2026 | -$0.14-27.3% vs -$0.11 | — vs $1M |
CTIM-76 weekly dosing at 140–280 µg in heavily pretreated PROC: 22% confirmed ORR, 56% confirmed DCR, and median PFS of 5.6 months

CDZI, CNSY and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2026.
ATS, CANG and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 13, 2026.
CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the first patient has been dosed in the Phase 1 clinical trial of CT-202, a Nectin-4 x CD3 TCE bispecific antibody.
Benchmark CNTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Context Therapeutics Inc. (CNTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.17 | $15.24M | -0.36 | — | — | -96.54% | — | |
| $6.29 | $261.93M | 18.64 | 10.37% | 20.98% | — | — | |
| $33.28 | $6.87B | -13.51 | — | -7173.52% | -63.01% | — | |
| $2.91 | $1.04M | -0.06 | -67.7% | -1578.79% | -91.95% | — | |
| $3.78 | $153.46M | 7.06 | 55.25% | 58.87% | 6.24% | 27.11% | |
| $30.15 | $1.79B | -4.83 | 48.03% | -264.76% | -34.63% | — |
Context Therapeutics Inc. (CNTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Context Therapeutics Inc. (CNTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 10, 2026·SEC
Aug 5, 2026·SEC
Jul 31, 2026·SEC
Get notified when CNTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Context Therapeutics Inc. (CNTX) stock FAQ — growth, dividends, profitability & financials explained
No. Context Therapeutics Inc. (CNTX) reported a net loss of $43.9M over the trailing twelve months.
Context Therapeutics Inc. (CNTX) had a return on equity (ROE) of -96.5% over the trailing twelve months. A negative ROE means the company lost money over the period.
Context Therapeutics Inc. (CNTX) had negative free cash flow of $34.0M over the trailing twelve months.